Developer docs
API playgroundTry for free, no card

Search company profiles

Pluto Biosciences

Full company profile

uuid000095z

Namestring
Pluto Biosciences
Legal namestring
Pluto Biosciences, Inc.
Websiteurl
pluto.bio
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Pluto Biosciences, Inc. (operating as Pluto Bio) is a Denver-based, Delaware-incorporated life sciences software company that develops a cloud-based, AI-native multi-omics analysis SaaS platform for translational discovery. The platform supports transcriptomics, proteomics, spatial omics, and multi-omics data integration, with end-to-end single-cell RNA-seq analysis, differential expression, pathway analysis, batch effect correction, and survival analysis capabilities built into a web application with API, Python SDK, and third-party integrations. Its core differentiator is a structured four-module Translational Decision framework (Therapeutic Hypothesis, Target Prioritization, Translational Confidence, Reverse Translation) that connects programs, experiments, datasets, decisions, and scientific evidence in a shared workspace, positioning the product as scientific program management infrastructure rather than a point bioinformatics tool.

The company sells primarily through an enterprise field sales motion targeting pharmaceutical and biotech companies, augmented by a self-serve Lab Space for organic adoption and a tiered referral program ($250-$500 per referral, or 10% commission for CRO/service providers). Revenue is generated via annual subscription SaaS agreements (per-seat and organizational tiers, quote-based and not publicly disclosed) supplemented by a Scientific Insights professional services offering that provides bioinformatics consulting. The customer base spans pharmaceutical companies (including Novo Nordisk, Nimbus Therapeutics, Septerna, Biomea Fusion, Prelude, and an unnamed Top 20 Pharma), academic and research institutions (Harvard, University of Michigan, MD Anderson Cancer Center, Wyss Institute, New York Blood Center), foundations, and CROs. The platform is SOC 2 Type II, GDPR, and CCPA compliant, with AES-256 encryption and continuous trust-center monitoring, supporting enterprise procurement and European data residency requirements.

Pluto was founded as a spinout from Harvard's Wyss Institute for Biologically Inspired Engineering and has raised approximately $8.3 million across three rounds ($1M seed in October 2021, $3.7M seed led by Silverton Partners in May 2023, and $3.6M led by Kickstart in May 2025). The company holds 11-50 employees, distributes primarily in North America with growing European coverage, and is led by Founder and CEO Rani Powers, PhD. Strategic distribution is anchored by a native integration with Benchling R&D Cloud and GraphPad Prism support, embedding Pluto within established R&D software stacks used by major pharma and biotech customers.

Short descriptiontext

Pluto Bio is a Denver-based, AI-native multi-omics SaaS platform for translational discovery, serving pharmaceutical, biotech, academic, and research institution customers with integrated omics analysis, decision-review modules, and Benchling-compatible workflows.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDenver, United States
HQ citystring
Denver
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multi-omics analysis software, bioinformatics SaaS platform, translational discovery platform, life sciences data analytics, AI drug discovery tools
Industry4 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers51321
  • Computer Systems Design and Related Services5415
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Bioinformatics & Multi-Omics Analytics Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1SaaS Subscription Services
TypeSubscription Recurring
Description

Subscription-based online services for organizing, storing, visualizing, and managing biological data. Subscription terms are annual with automatic renewal. Revenue is generated through per-seat licensing and volume-based tiers for organizations of different sizes.

pluto.bio
2Professional Services
TypeProfessional Services
Description

Implementation, configuration, integration, training, and bioinformatics advisory services provided under Statements of Work. Includes Scientific Insights team offering bioinformatics consulting and professional services to augment in-house capabilities of pharma customers.

pluto.bio
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Pricing details2 tiers
1Subscription-based platform with annual billing and automatic renewal for successive one-year terms
ModelSubscriptionBilling cadenceAnnual
Notes

Fees are non-cancellable and non-refundable once paid. Pluto may increase fees for renewal terms with 45 days' written notice. Annual subscription model with per-seat or organizational tiers implied by SysAdmin console-based usage limitations.

pluto.bio
2Referral program tiers: Promoter ($250 per referral for contracts up to $25k/year), Catalyst ($500 per referral for contracts >$25k/year), Symbiosis (10% commission for CROs/service providers)
ModelSubscriptionBilling cadenceAnnual
Notes

Rewards provided as Visa or Amazon gift cards. New client must mention referrer's name prior to contract signing. Offer applies to new Pluto clients only.

pluto.bio
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Pluto Biosciences sells a cloud-based, AI-native multi-omics SaaS platform that enables translational research teams in pharma, biotech, and academia to organize, analyze, visualize, and manage biological data (transcriptomics, proteomics, spatial omics, multi-omics) and make structured go/no-go decisions across therapeutic hypothesis, target prioritization, translational confidence, and reverse translation. The platform is offered via annual subscription with a web app, REST API, Python SDK, and native Benchling integration, supplemented by Scientific Insights professional services for bioinformatics consulting.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 90% of scientists at a Top 20 Pharma company agreed that Pluto increased efficiency in their scientific work
Product overview1 text field

Pluto Bio is a unified multi-omics platform for translational discovery, combining AI-powered analysis, collaborative workflows, and decision support modules. The core product encompasses the Pluto Bio Platform with four structured decision reviews (Therapeutic Hypothesis, Target Prioritization, Translational Confidence, Reverse Translation), the Research Assistant for AI-powered insights, and the Scientific Insights consulting team. Key capabilities include end-to-end scRNA-seq analysis, batch effect correction, multi-omics integration (RNA-seq, ATAC-seq, ChIP-seq, proteomics), survival analysis, and differential expression analysis. The platform also offers Labspace as the user workspace, API & SDKs for programmatic access, and integration support for Benchling and GraphPad Prism.

Product and service5 records
1Pluto Bio Platform
CategoryMulti-omics analysis SaaS platform
Description

Core AI-powered, multi-omics SaaS platform for translational discovery that enables scientific teams to organize, analyze, visualize, and manage biological data (transcriptomics, proteomics, spatial, multi-omics) in a unified environment, with four structured Translational Decision modules, AI Research Assistant, and Scientific Canvas. Sold via annual subscription to pharma, biotech, academic, CRO, and foundation customers.

2Pluto API & SDKs
CategoryDeveloper API and SDK product
Description

Programmatic developer product exposing Pluto's multi-omics data, analyses, and visualizations via REST API and Python SDK so developers can run custom analyses outside the web app and push results back into Pluto.

3End-to-End scRNA-seq Analysis
CategorySingle-cell omics analysis capability
Description

End-to-end single-cell RNA sequencing analysis capability within Pluto, supporting comprehensive scRNA-seq data processing, marker gene expression analysis with UMAP/ridge/violin plots, and biomarker discovery for translational research teams.

4Labspace
CategoryUser workspace and self-serve entry point
Description

User workspace within Pluto (app.pluto.bio) where individual users access experiments, analyses, collaborative tools, compute, and storage; also the entry point for self-serve exploration of the platform.

5Scientific Insights (Professional Services)
CategoryProfessional bioinformatics services
Description

Statement-of-Work bioinformatics consulting and professional services team that augments customer in-house bioinformatics expertise with implementation, configuration, integration, training, and bespoke analysis support.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Wyss Institute for Biologically Inspired Engineering at Harvard University is the founding institution of Pluto Biosciences. The Wyss Brain Targeting Program uses Pluto's target discovery platform to analyze omics data, integrate literature evidence, and identify genes and proteins for brain drug delivery. The relationship includes published research citing Pluto (Nature Communications, Cardiovascular Research).

Strategic tierCoreTypeTechnology or Integration
Description

Native product integration with Benchling R&D Cloud. The integration allows users to sync interactive Pluto visualizations directly to Benchling, connecting bioinformatics analysis outputs with electronic lab notebooks and R&D workflows used by major pharma and biotech companies.

Strategic tierMinorTypeOthers
Description

Referenced alongside Pluto in a Harvard article discussing the convergence of AI, cloud computing, and accessible software platforms transforming biological research. Listed as peer platforms in the democratized computational biology ecosystem, not formal partners.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cloud-based R&D platform for life sciences with electronic lab notebooks, LIMS, and registry capabilities. Directly comparable because Pluto integrates with Benchling and competes for the same translational R&D software budget within pharma and biotech organizations.

TypeDirect peer
Description

Scientific informatics platform for R&D spanning ELN, data management, and analytics. Directly comparable as a life sciences R&D SaaS suite targeting similar pharma and biotech translational research workflows.

TypeDirect peer
Description

Cloud-based genomics and multi-omics data analysis platform. Directly comparable as cloud-hosted bioinformatics infrastructure used by pharma and clinical research organizations to manage and analyze large-scale omics data.

TypeDirect peer
Description

Enterprise bioinformatics and R&D data analytics platform serving pharma and biotech. Directly comparable as a multi-omics and translational data management software provider with similar enterprise customer base.

TypeBroad incumbent
Description

Established computational chemistry, molecular simulation, and AI drug discovery platform. Comparable as a broader, well-capitalized incumbent offering AI-enabled discovery and informatics solutions that overlap with Pluto's AI-native translational discovery positioning.

6Sapio Sciences
TypeDirect peer
Description

Lab informatics platform combining ELN, LIMS, and scientific data management for life sciences. Comparable as a direct peer offering scientific data management and analysis solutions to pharma and biotech R&D organizations.

TypeEmerging player
Description

Workflow orchestration and data analysis platform for genomics and multi-omics. Comparable as an emerging player enabling reproducible computational biology pipelines for translational and clinical research teams.

TypeEmerging player
Description

Computational biology platform supporting multi-omics workflows and analyses. Comparable as an emerging player in cloud-based bioinformatics and omics analysis tooling for life sciences researchers.

TypeEmerging player
Description

Cloud-based computational reproducibility and collaboration platform for scientific research. Comparable as an emerging player offering compute, data management, and reproducibility features used alongside multi-omics workflows.

TypeBroad incumbent
Description

Bioinformatics and data analysis offerings from QIAGEN spanning genomics, interpretation, and clinical insights. Comparable as a broader incumbent providing multi-omics analysis and interpretation software widely used in translational research.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pluto Biosciences

Bioinformatics & Multi-Omics Analytics Softwarepluto.bio

Pluto Bio is a Denver-based, AI-native multi-omics SaaS platform for translational discovery, serving pharmaceutical, biotech, academic, and research institution customers with integrated omics analysis, decision-review modules, and Benchling-compatible workflows.

What Pluto Biosciences does

Pluto Biosciences, Inc. (operating as Pluto Bio) is a Denver-based, Delaware-incorporated life sciences software company that develops a cloud-based, AI-native multi-omics analysis SaaS platform for translational discovery. The platform supports transcriptomics, proteomics, spatial omics, and multi-omics data integration, with end-to-end single-cell RNA-seq analysis, differential expression, pathway analysis, batch effect correction, and survival analysis capabilities built into a web application with API, Python SDK, and third-party integrations. Its core differentiator is a structured four-module Translational Decision framework (Therapeutic Hypothesis, Target Prioritization, Translational Confidence, Reverse Translation) that connects programs, experiments, datasets, decisions, and scientific evidence in a shared workspace, positioning the product as scientific program management infrastructure rather than a point bioinformatics tool.

The company sells primarily through an enterprise field sales motion targeting pharmaceutical and biotech companies, augmented by a self-serve Lab Space for organic adoption and a tiered referral program ($250-$500 per referral, or 10% commission for CRO/service providers). Revenue is generated via annual subscription SaaS agreements (per-seat and organizational tiers, quote-based and not publicly disclosed) supplemented by a Scientific Insights professional services offering that provides bioinformatics consulting. The customer base spans pharmaceutical companies (including Novo Nordisk, Nimbus Therapeutics, Septerna, Biomea Fusion, Prelude, and an unnamed Top 20 Pharma), academic and research institutions (Harvard, University of Michigan, MD Anderson Cancer Center, Wyss Institute, New York Blood Center), foundations, and CROs. The platform is SOC 2 Type II, GDPR, and CCPA compliant, with AES-256 encryption and continuous trust-center monitoring, supporting enterprise procurement and European data residency requirements.

Pluto was founded as a spinout from Harvard's Wyss Institute for Biologically Inspired Engineering and has raised approximately $8.3 million across three rounds ($1M seed in October 2021, $3.7M seed led by Silverton Partners in May 2023, and $3.6M led by Kickstart in May 2025). The company holds 11-50 employees, distributes primarily in North America with growing European coverage, and is led by Founder and CEO Rani Powers, PhD. Strategic distribution is anchored by a native integration with Benchling R&D Cloud and GraphPad Prism support, embedding Pluto within established R&D software stacks used by major pharma and biotech customers.

Pluto Biosciences firmographics

Firmographics
Name
Pluto Biosciences
Legal name
Pluto Biosciences, Inc.
Website
https://pluto.bio
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Pluto Bio is a Denver-based, AI-native multi-omics SaaS platform for translational discovery, serving pharmaceutical, biotech, academic, and research institution customers with integrated omics analysis, decision-review modules, and Benchling-compatible workflows.
Ownership category
akta.pro rank

Pluto Biosciences industry classification

Industry
Product category
Bioinformatics & Multi-Omics Analytics Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (51321), Computer Systems Design and Related Services (5415)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Multi-omics analysis software
  • Bioinformatics SaaS platform
  • Translational discovery platform
  • Life sciences data analytics
  • AI drug discovery tools

Where Pluto Biosciences is headquartered

Location

Headquarters

HQ city
Denver
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Pluto Biosciences business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. SaaS Subscription Services: Subscription-based online services for organizing, storing, visualizing, and managing biological data. Subscription terms are annual with automatic renewal. Revenue is generated through per-seat licensing and volume-based tiers for organizations of different sizes.
  2. Professional Services: Implementation, configuration, integration, training, and bioinformatics advisory services provided under Statements of Work. Includes Scientific Insights team offering bioinformatics consulting and professional services to augment in-house capabilities of pharma customers.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualSubscription-based platform with annual billing and automatic renewal for successive one-year terms
SubscriptionAnnualReferral program tiers: Promoter ($250 per referral for contracts up to $25k/year), Catalyst ($500 per referral for contracts >$25k/year), Symbiosis (10% commission for CROs/service providers)

Go-to-market motion2 records

Distribution channels3 records

Marketing channels10 records

Pluto Biosciences product offering

Product offering

Core offering

Pluto Biosciences sells a cloud-based, AI-native multi-omics SaaS platform that enables translational research teams in pharma, biotech, and academia to organize, analyze, visualize, and manage biological data (transcriptomics, proteomics, spatial omics, multi-omics) and make structured go/no-go decisions across therapeutic hypothesis, target prioritization, translational confidence, and reverse translation. The platform is offered via annual subscription with a web app, REST API, Python SDK, and native Benchling integration, supplemented by Scientific Insights professional services for bioinformatics consulting.

Product overview

Pluto Bio is a unified multi-omics platform for translational discovery, combining AI-powered analysis, collaborative workflows, and decision support modules. The core product encompasses the Pluto Bio Platform with four structured decision reviews (Therapeutic Hypothesis, Target Prioritization, Translational Confidence, Reverse Translation), the Research Assistant for AI-powered insights, and the Scientific Insights consulting team. Key capabilities include end-to-end scRNA-seq analysis, batch effect correction, multi-omics integration (RNA-seq, ATAC-seq, ChIP-seq, proteomics), survival analysis, and differential expression analysis. The platform also offers Labspace as the user workspace, API & SDKs for programmatic access, and integration support for Benchling and GraphPad Prism.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pluto Bio Platform Core AI-powered, multi-omics SaaS platform for translational discovery that enables scientific teams to organize, analyze, visualize, and manage biological data (transcriptomics, proteomics, spatial, multi-omics) in a unified environment, with four structured Translational Decision modules, AI Research Assistant, and Scientific Canvas. Sold via annual subscription to pharma, biotech, academic, CRO, and foundation customers.
  • Pluto API & SDKs Programmatic developer product exposing Pluto's multi-omics data, analyses, and visualizations via REST API and Python SDK so developers can run custom analyses outside the web app and push results back into Pluto.
  • End-to-End scRNA-seq Analysis End-to-end single-cell RNA sequencing analysis capability within Pluto, supporting comprehensive scRNA-seq data processing, marker gene expression analysis with UMAP/ridge/violin plots, and biomarker discovery for translational research teams.
  • Labspace User workspace within Pluto (app.pluto.bio) where individual users access experiments, analyses, collaborative tools, compute, and storage; also the entry point for self-serve exploration of the platform.
  • Scientific Insights (Professional Services) Statement-of-Work bioinformatics consulting and professional services team that augments customer in-house bioinformatics expertise with implementation, configuration, integration, training, and bespoke analysis support.

Quantifiable outcome

  • 90% of scientists at a Top 20 Pharma company agreed that Pluto increased efficiency in their scientific work

Companies that use Pluto Biosciences

Customer profile

Named customers12 records

Segments4 records

Ideal customer profiles4 records

Pluto Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability8 records

Feature9 records

Pluto Biosciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Wyss Institute at HarvardcoreStrategic or Co-development PartnerThe Wyss Institute for Biologically Inspired Engineering at Harvard University is the founding institution of Pluto Biosciences. The Wyss Brain Targeting Program uses Pluto's target discovery platform to analyze omics data, integrate literature evidence, and identify genes and proteins for brain drug delivery. The relationship includes published research citing Pluto (Nature Communications, Cardiovascular Research).
  • BenchlingcoreTechnology or IntegrationNative product integration with Benchling R&D Cloud. The integration allows users to sync interactive Pluto visualizations directly to Benchling, connecting bioinformatics analysis outputs with electronic lab notebooks and R&D workflows used by major pharma and biotech companies.
  • Seqera Labs, Form Bio, Code Ocean, Galaxy, BioconductorminorOthersReferenced alongside Pluto in a Harvard article discussing the convergence of AI, cloud computing, and accessible software platforms transforming biological research. Listed as peer platforms in the democratized computational biology ecosystem, not formal partners.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Pluto Biosciences competitors and assessment

Company assessment

Direct peers

  • Benchling: Cloud-based R&D platform for life sciences with electronic lab notebooks, LIMS, and registry capabilities. Directly comparable because Pluto integrates with Benchling and competes for the same translational R&D software budget within pharma and biotech organizations.
  • Dotmatics: Scientific informatics platform for R&D spanning ELN, data management, and analytics. Directly comparable as a life sciences R&D SaaS suite targeting similar pharma and biotech translational research workflows.
  • DNAnexus: Cloud-based genomics and multi-omics data analysis platform. Directly comparable as cloud-hosted bioinformatics infrastructure used by pharma and clinical research organizations to manage and analyze large-scale omics data.
  • Genedata: Enterprise bioinformatics and R&D data analytics platform serving pharma and biotech. Directly comparable as a multi-omics and translational data management software provider with similar enterprise customer base.
  • Sapio Sciences: Lab informatics platform combining ELN, LIMS, and scientific data management for life sciences. Comparable as a direct peer offering scientific data management and analysis solutions to pharma and biotech R&D organizations.

Broad incumbents

  • Schrödinger: Established computational chemistry, molecular simulation, and AI drug discovery platform. Comparable as a broader, well-capitalized incumbent offering AI-enabled discovery and informatics solutions that overlap with Pluto's AI-native translational discovery positioning.
  • QIAGEN Digital Insights (QIAGEN): Bioinformatics and data analysis offerings from QIAGEN spanning genomics, interpretation, and clinical insights. Comparable as a broader incumbent providing multi-omics analysis and interpretation software widely used in translational research.

Emerging players

  • Seqera Labs: Workflow orchestration and data analysis platform for genomics and multi-omics. Comparable as an emerging player enabling reproducible computational biology pipelines for translational and clinical research teams.
  • Form Bio: Computational biology platform supporting multi-omics workflows and analyses. Comparable as an emerging player in cloud-based bioinformatics and omics analysis tooling for life sciences researchers.
  • Code Ocean: Cloud-based computational reproducibility and collaboration platform for scientific research. Comparable as an emerging player offering compute, data management, and reproducibility features used alongside multi-omics workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Pluto Biosciences social profiles

Digital presence

Pluto Biosciences compliance and trust

Trust signal

Compliance3 records

Pluto Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pluto Biosciences leadership team

Management profile

Number of profiles

Profiles2 records

Pluto Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pluto Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pluto Biosciences

What does Pluto Biosciences do?

Pluto Biosciences sells a cloud-based, AI-native multi-omics SaaS platform that enables translational research teams in pharma, biotech, and academia to organize, analyze, visualize, and manage biological data (transcriptomics, proteomics, spatial omics, multi-omics) and make structured go/no-go decisions across therapeutic hypothesis, target prioritization, translational confidence, and reverse translation. The platform is offered via annual subscription with a web app, REST API, Python SDK, and native Benchling integration, supplemented by Scientific Insights professional services for bioinformatics consulting.

Is Pluto Biosciences a public or private company?

Pluto Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pluto Biosciences founded?

Pluto Biosciences was founded in 2021. It employs 11 to 50 people.

Where is Pluto Biosciences based?

Pluto Biosciences is headquartered in Denver, United States, in the North America region.

How does Pluto Biosciences make money?

Two revenue lines are on record. SaaS Subscription Services are the primary driver. The others are professional Services.

Who are Pluto Biosciences's main competitors?

Direct peers on record are Benchling, Dotmatics, DNAnexus, Genedata and Sapio Sciences. Broad incumbents are Schrödinger and QIAGEN Digital Insights (QIAGEN). Emerging players are Seqera Labs, Form Bio and Code Ocean.

Does Pluto Biosciences have an API?

Yes. Pluto offers an API and SDKs for developers to programmatically access data in Pluto, enabling custom analyses and visualizations not supported in-app. Developers can push custom analysis results and plots back to Pluto to view alongside in-app analyses. The October 2023 product update mentions SDK availability. Documentation available at docs.pluto.bio. Developer documentation is at docs.pluto.bio.

What industry is Pluto Biosciences in?

Pluto Biosciences's product category is Bioinformatics & Multi-Omics Analytics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AI InsiderPluto Bio Raises $3.6M to Expand AI-Powered Multi-Omics Analysis Platform for PharmaPluto Bio raised $3.6 million in new funding from Kickstart, Silverton Partners, and angel investors to expand its AI-powered computational biology platform for pharma. The platform enables scientists to analyze multi-omics data without coding, supporting target discovery and biomarker research. The capital will fund AI agent development, R&D tool integrations, and commercial scaling.citybizPluto Bio Raises $3.6M FundingPluto Bio raised $3.6 million in new funding led by Kickstart, with participation from Silverton Partners and existing angel investors. The capital will support development of AI agents and copilots, expansion of integrations, and commercial build-out. The company aims to accelerate deployment across therapeutic areas and modalities.Business Wire BlogPluto Bio Raises $3.6M to Expand AI-Powered Multi-Omics Analysis Platform for PharmaPluto Bio raised $3.6 million in new funding, with participation from Kickstart and existing investors, to accelerate growth and scale adoption of its AI-powered multi-omics platform among pharma companies. The capital will support development of AI agents, integrations, and commercial roles.YahooPluto Bio Raises $3.6M to Expand AI-Powered Multi-Omics Analysis Platform for PharmaPluto Bio announced it has raised $3.6 million in funding to enhance its AI-powered platform for computational biology aimed at global pharma companies. New investor Kickstart led the funding round, which included continued support from Silverton Partners, to accelerate the platform's growth and adoption in drug discovery. The funding will enable Pluto to expand its AI agents, integrate with other R&D tools, and broaden its commercial capabilities across therapeutic areas.PlutoPluto Bio • Navigating the NIH's updated genomic data secu...The National Institutes of Health (NIH) is implementing updated security best practices for its Genomic Data Sharing policy on January 25, 2025, requiring stricter compliance with NIST SP 800-171 standards for handling controlled-access human genomic data. These changes mandate that principal investigators and their institutions, including those using third-party platforms, attest to the security of their data storage and analysis systems to mitigate cyber threats. The article highlights how compliant infrastructure providers can assist researchers in meeting these new regulatory requirements efficiently.PlutoPluto Bio • Using Multi-Omics Approaches for Effective Tar...Pluto Bio is promoting its multi-omics platform, Pluto, designed to help biotechnology companies integrate genomics, transcriptomics, and other molecular data for drug target discovery. The company highlights the platform's ability to automate complex bioinformatics analysis, allowing research teams to validate targets and stratify patients without requiring extensive coding or infrastructure.Harvard GazetteFrom Bits to Biology: A New Era of Biological Renaissance powered by AIThe author argues that the convergence of AI, cloud computing, and accessible software platforms is fundamentally transforming biological research by blurring traditional boundaries between computational (in silico), experimental (in vitro), and clinical (in vivo) approaches. The article highlights emerging platforms like Seqera Labs, Form Bio, Code Ocean, and Pluto Biosciences, along with open-source tools such as Galaxy and Bioconductor, as examples of how democratized access to computational biology tools is accelerating scientific discovery. The author contends that this shift toward user-friendly, collaborative, and AI-integrated platforms is ushering in a new era of faster, more efficient, and more inclusive scientific breakthroughs in fields ranging from drug discovery to personalized medicine.SecSEC FORM DPluto Biosciences, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The filing indicates that $3,704,373 USD was raised from 14 investors, with sales commencing on May 1, 2023. This regulatory submission formalizes the company's private capital raise activities.dlvr.itPluto Biosciences: $3.7 Million Secured For Life Sciences SaaS PlatformPluto Biosciences closed a $3.7 million seed round led by Silverton Partners. The funding will support product and go-to-market expansion for its life sciences SaaS platform. The company plans to develop advanced features and increase sales velocity.Pulse 2.0Pluto Biosciences: $3.7 Million Secured For Life Sciences SaaS PlatformPluto Biosciences closed a $3.7 million seed round led by Silverton Partners. The funding will support product and go-to-market expansion for its life sciences SaaS platform. The company plans to develop advanced features and increase sales velocity.